Publication

Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET: a multicenter analysis

Jauw, Y. W. S., Bensch, F., Brouwers, A. H., Hoekstra, O. S., Zijlstra, J. M., Pieplenbosch, S., Schroder, C. P., Zweegman, S., van Dongen, G. A. M. S., van Oordt, C. W. M. D. H., de Vries, E. G. E., de Vet, H. C. W., Boellaard, R. & Huisman, M. C., Aug-2019, In : European Journal of Nuclear Medicine and Molecular Imaging. 46, 9, p. 1840-1849 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Jauw, Y. W. S., Bensch, F., Brouwers, A. H., Hoekstra, O. S., Zijlstra, J. M., Pieplenbosch, S., ... Huisman, M. C. (2019). Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET: a multicenter analysis. European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1840-1849. https://doi.org/10.1007/s00259-019-04377-6

Author

Jauw, Yvonne W. S. ; Bensch, Frederike ; Brouwers, Adrienne H. ; Hoekstra, Otto S. ; Zijlstra, Josee M. ; Pieplenbosch, Simone ; Schroder, Carolien P. ; Zweegman, Sonja ; van Dongen, Guus A. M. S. ; van Oordt, C. Willemien Menke-van der Houven ; de Vries, Elisabeth G. E. ; de Vet, Henrica C. W. ; Boellaard, Ronald ; Huisman, Marc C. / Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET : a multicenter analysis. In: European Journal of Nuclear Medicine and Molecular Imaging. 2019 ; Vol. 46, No. 9. pp. 1840-1849.

Harvard

Jauw, YWS, Bensch, F, Brouwers, AH, Hoekstra, OS, Zijlstra, JM, Pieplenbosch, S, Schroder, CP, Zweegman, S, van Dongen, GAMS, van Oordt, CWMDH, de Vries, EGE, de Vet, HCW, Boellaard, R & Huisman, MC 2019, 'Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET: a multicenter analysis', European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 9, pp. 1840-1849. https://doi.org/10.1007/s00259-019-04377-6

Standard

Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET : a multicenter analysis. / Jauw, Yvonne W. S.; Bensch, Frederike; Brouwers, Adrienne H.; Hoekstra, Otto S.; Zijlstra, Josee M.; Pieplenbosch, Simone; Schroder, Carolien P.; Zweegman, Sonja; van Dongen, Guus A. M. S.; van Oordt, C. Willemien Menke-van der Houven; de Vries, Elisabeth G. E.; de Vet, Henrica C. W.; Boellaard, Ronald; Huisman, Marc C.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, No. 9, 08.2019, p. 1840-1849.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Jauw YWS, Bensch F, Brouwers AH, Hoekstra OS, Zijlstra JM, Pieplenbosch S et al. Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET: a multicenter analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2019 Aug;46(9):1840-1849. https://doi.org/10.1007/s00259-019-04377-6


BibTeX

@article{7c7a747739674a3795191b1b2f612081,
title = "Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET: a multicenter analysis",
abstract = "PurposeIn-vivo quantification of tumor uptake of 89-zirconium (Zr-89)-labelled monoclonal antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for Zr-89-immuno-PET is low tumor contrast. This is expected to result in interobserver variation in tumor delineation. Therefore, the aim of this study was to determine interobserver reproducibility of tumor uptake measures by tumor delineation on Zr-89-immuno-PET scans.MethodsData were obtained from previously published clinical studies performed with Zr-89-rituximab, Zr-89-cetuximab and Zr-89-trastuzumab. Tumor lesions on Zr-89-immuno-PET were identified as focal uptake exceeding local background by a nuclear medicine physician. Three observers independently manually delineated volumes of interest (VOI). Maximum, peak and mean standardized uptake values (SUVmax, SUVpeak and SUVmean) were used to quantify tumor uptake. Interobserver variability was expressed as the coefficient of variation (CoV). The performance of semi-automatic VOI delineation using 50{\%} of background-corrected AC(peak) was described.ResultsIn total, 103 VOI were delineated (3-6days post injection (D3-D6)). Tumor uptake (median, interquartile range) was 9.2 (5.2-12.6), 6.9 (4.0-9.6) and 5.5 (3.3-7.8) for SUVmax, SUVpeak and SUVmean. Interobserver variability was 0{\%} (0-12), 0{\%} (0-2) and 7{\%} (5-14), respectively (n=103). The success rate of the semi-automatic method was 45{\%}. Inclusion of background was the main reason for failure of semi-automatic VOI.ConclusionsThis study shows that interobserver reproducibility of tumor uptake quantification on Zr-89-immuno-PET was excellent for SUVmax and SUVpeak using a standardized manual procedure for tumor segmentation. Semi-automatic delineation was not robust due to limited tumor contrast.",
keywords = "Monoclonal antibodies, PET, (89)Zirconium, Immuno-PET, Reproducibility, POSITRON-EMISSION-TOMOGRAPHY, PET/CT",
author = "Jauw, {Yvonne W. S.} and Frederike Bensch and Brouwers, {Adrienne H.} and Hoekstra, {Otto S.} and Zijlstra, {Josee M.} and Simone Pieplenbosch and Schroder, {Carolien P.} and Sonja Zweegman and {van Dongen}, {Guus A. M. S.} and {van Oordt}, {C. Willemien Menke-van der Houven} and {de Vries}, {Elisabeth G. E.} and {de Vet}, {Henrica C. W.} and Ronald Boellaard and Huisman, {Marc C.}",
year = "2019",
month = "8",
doi = "10.1007/s00259-019-04377-6",
language = "English",
volume = "46",
pages = "1840--1849",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "SPRINGER",
number = "9",

}

RIS

TY - JOUR

T1 - Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET

T2 - a multicenter analysis

AU - Jauw, Yvonne W. S.

AU - Bensch, Frederike

AU - Brouwers, Adrienne H.

AU - Hoekstra, Otto S.

AU - Zijlstra, Josee M.

AU - Pieplenbosch, Simone

AU - Schroder, Carolien P.

AU - Zweegman, Sonja

AU - van Dongen, Guus A. M. S.

AU - van Oordt, C. Willemien Menke-van der Houven

AU - de Vries, Elisabeth G. E.

AU - de Vet, Henrica C. W.

AU - Boellaard, Ronald

AU - Huisman, Marc C.

PY - 2019/8

Y1 - 2019/8

N2 - PurposeIn-vivo quantification of tumor uptake of 89-zirconium (Zr-89)-labelled monoclonal antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for Zr-89-immuno-PET is low tumor contrast. This is expected to result in interobserver variation in tumor delineation. Therefore, the aim of this study was to determine interobserver reproducibility of tumor uptake measures by tumor delineation on Zr-89-immuno-PET scans.MethodsData were obtained from previously published clinical studies performed with Zr-89-rituximab, Zr-89-cetuximab and Zr-89-trastuzumab. Tumor lesions on Zr-89-immuno-PET were identified as focal uptake exceeding local background by a nuclear medicine physician. Three observers independently manually delineated volumes of interest (VOI). Maximum, peak and mean standardized uptake values (SUVmax, SUVpeak and SUVmean) were used to quantify tumor uptake. Interobserver variability was expressed as the coefficient of variation (CoV). The performance of semi-automatic VOI delineation using 50% of background-corrected AC(peak) was described.ResultsIn total, 103 VOI were delineated (3-6days post injection (D3-D6)). Tumor uptake (median, interquartile range) was 9.2 (5.2-12.6), 6.9 (4.0-9.6) and 5.5 (3.3-7.8) for SUVmax, SUVpeak and SUVmean. Interobserver variability was 0% (0-12), 0% (0-2) and 7% (5-14), respectively (n=103). The success rate of the semi-automatic method was 45%. Inclusion of background was the main reason for failure of semi-automatic VOI.ConclusionsThis study shows that interobserver reproducibility of tumor uptake quantification on Zr-89-immuno-PET was excellent for SUVmax and SUVpeak using a standardized manual procedure for tumor segmentation. Semi-automatic delineation was not robust due to limited tumor contrast.

AB - PurposeIn-vivo quantification of tumor uptake of 89-zirconium (Zr-89)-labelled monoclonal antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for Zr-89-immuno-PET is low tumor contrast. This is expected to result in interobserver variation in tumor delineation. Therefore, the aim of this study was to determine interobserver reproducibility of tumor uptake measures by tumor delineation on Zr-89-immuno-PET scans.MethodsData were obtained from previously published clinical studies performed with Zr-89-rituximab, Zr-89-cetuximab and Zr-89-trastuzumab. Tumor lesions on Zr-89-immuno-PET were identified as focal uptake exceeding local background by a nuclear medicine physician. Three observers independently manually delineated volumes of interest (VOI). Maximum, peak and mean standardized uptake values (SUVmax, SUVpeak and SUVmean) were used to quantify tumor uptake. Interobserver variability was expressed as the coefficient of variation (CoV). The performance of semi-automatic VOI delineation using 50% of background-corrected AC(peak) was described.ResultsIn total, 103 VOI were delineated (3-6days post injection (D3-D6)). Tumor uptake (median, interquartile range) was 9.2 (5.2-12.6), 6.9 (4.0-9.6) and 5.5 (3.3-7.8) for SUVmax, SUVpeak and SUVmean. Interobserver variability was 0% (0-12), 0% (0-2) and 7% (5-14), respectively (n=103). The success rate of the semi-automatic method was 45%. Inclusion of background was the main reason for failure of semi-automatic VOI.ConclusionsThis study shows that interobserver reproducibility of tumor uptake quantification on Zr-89-immuno-PET was excellent for SUVmax and SUVpeak using a standardized manual procedure for tumor segmentation. Semi-automatic delineation was not robust due to limited tumor contrast.

KW - Monoclonal antibodies

KW - PET

KW - (89)Zirconium

KW - Immuno-PET

KW - Reproducibility

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - PET/CT

U2 - 10.1007/s00259-019-04377-6

DO - 10.1007/s00259-019-04377-6

M3 - Article

VL - 46

SP - 1840

EP - 1849

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 9

ER -

ID: 95559135